文献速递肺结节与肺癌慢阻肺

年轻肺癌患者中大麻与烟草双重吸烟的影响:前瞻性「环境与肺癌」研究结果

The Impact of Dual Cannabis and Tobacco Smoking in Young Patients With Lung Cancer: Results From the Prospective "Environment and Lung Cancer" Study.
PubMed 文献 · Chest · 2025-09-24

这项多中心前瞻性研究纳入150例≤60岁初诊原发性肺癌患者,通过毛发检测确认吸烟行为。148例可分析患者中39%为大麻与烟草双重吸烟者,52%为单纯烟草吸烟者,9%为不吸烟者。双重吸烟者较单纯烟草吸烟者更年轻、胸痛更多、罕见侵袭性肺癌比例更高、肺气肿更多且气体弥散功能更低。

要点

  • 年轻肺癌患者中大麻与烟草双重吸烟者占39%,所有大麻吸烟者均同时吸烟草。
  • 双重吸烟者罕见侵袭性肺癌比例17% vs 单纯烟草吸烟者4%,肺气肿64% vs 38%。
  • 双重吸烟者诊断时更年轻(中位53岁 vs 56岁)且胸痛更常见(22% vs 8%)。

核心结论

  • 年轻肺癌患者中大麻与烟草双重吸烟高度流行,且与单纯烟草吸烟者相比具有独特的临床模式。

研究设计与样本

  • 多中心前瞻性研究,纳入2021至2023年间连续诊断的150例年龄≤60岁原发性肺癌患者。
  • 吸烟行为通过自我报告及毛发检测尼古丁、可替宁、四氢大麻酚和大麻二酚确认。

主要发现

  • 148例可分析患者中,39%为大麻与烟草双重吸烟者,52%为单纯烟草吸烟者,9%为不吸烟者。
  • 双重吸烟者大麻使用量大(中位持续时间26年,每日4支)。
  • 双重吸烟者较单纯烟草吸烟者更年轻(中位53岁 vs 56岁,P = .006),诊断时胸痛更常见(22% vs 8%,P = .03)。
  • 双重吸烟者罕见侵袭性肺癌比例更高(17% vs 4%,P = .007),肺气肿更多(64% vs 38%,P = .003),气体弥散功能更低(63% vs 70%,P = .004)。

临床怎么用

  • 对年轻肺癌患者应详细询问大麻使用史,并考虑将其纳入吸烟暴露评估。
  • 双重吸烟者可能具有更年轻发病、更多肺气肿及侵袭性肿瘤类型的特征,需加强关注。

局限性

  • 原文指出需进一步研究以确定大麻对肺癌的独立效应及其对患者管理的潜在影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of cannabis smoking in lung cancer has long been underexplored due to its historical illegality and frequent co-use with tobacco. As cannabis use increases globally, particularly among younger individuals, understanding its impact on lung cancer is critical. RESEARCH QUESTION: What is the prevalence of cannabis smoking in young patients with lung cancer? What are the precise characteristics of lung cancer in patients who smoke cannabis? STUDY DESIGN AND METHODS: This multicenter prospective study included 150 patients aged ≤ 60 years consecutively diagnosed with primary lung cancer between 2021 and 2023. Smoking behaviors were self-reported and confirmed by hair testing for nicotine, cotinine (a nicotine metabolite), tetrahydrocannabinol, and cannabidiol (cannabis active ingredients). Participants were categorized as patients who smoke cannabis and tobacco (CTSs), patients who smoke exclusively tobacco (TSs), and patients who do not smoke. Clinical features, tumor characteristics, and surgical outcomes were compared between groups. RESULTS: Of 148 study patients, 39% were CTSs, 52% were TSs, and 9% were patients who do not smoke. All patients who smoke cannabis also smoked tobacco, with no difference in self-reported pack-years and hair cotinine concentrations compared with TSs. Cannabis use in CTSs was heavy (median duration, 26 years; 4 joints per day). Compared with TSs, CTSs were younger (median age, 53 years vs 56 years; P = .006) and more often reported chest pain at diagnosis (22% vs 8%; P = .03). They also had higher rates of rare and aggressive lung cancers (17% vs 4%; P = .007), more emphysema (64% vs 38%; P = .003), and lower gas diffusion capacity (63% vs 70%; P = .004). INTERPRETATION: Our results show that dual cannabis and tobacco smoking is highly prevalent in young patients with lung cancer and is associated with distinct clinical patterns compared with those of TSs, including a higher incidence of emphysema and aggressive tumor types. Further studies are needed to determine the independent effects of cannabis on lung cancer and its potential impact on patient management.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Pradère P, Marinello A, Vasseur D, et al. The Impact of Dual Cannabis and Tobacco Smoking in Young Patients With Lung Cancer: Results From the Prospective "Environment and Lung Cancer" Study. Chest. 2025. PMID: 41005696. doi:10.1016/j.chest.2025.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。